Kallyope Inc., a NYC-based biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, raised $66m in Series B financing.
Backers included Lux Capital, The Column Group, Polaris Partners, Illumina Ventures, and Alexandria Venture Investments as well as new investors Euclidean Capital and Two Sigma Ventures.
The company will use the funds to expand operations expecting to grow to nearly 60 employees by the end of 2018.
Co-founded by Charles Zuker, Ph.D., Tom Maniatis, Ph.D., and Richard Axel, M.D., and led by CEO Nancy Thornberry, Kallyope is a platform biotechnology company focused on advancing therapeutics for gut-brain axis. A cross-disciplinary team integrates technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that aims to lead to transformational therapeutics to improve human health. Initially, the company will focus on metabolic and neurological disorders to later expand to virtually every disease area involving the gut and gut-brain axis.